NTRK Alterations in pediatric high-risk malignancies identified through European clinical sequencing programs constitute promising drug targets
(2021) In JCO Precision Oncology 5. p.450-454
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/d416dff8-f85a-4184-b7a0-eccbca4a5171
- author
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- in
- JCO Precision Oncology
- volume
- 5
- pages
- 5 pages
- publisher
- American Society of Clinical Oncology
- external identifiers
-
- pmid:34994601
- scopus:85103177804
- ISSN
- 2473-4284
- DOI
- 10.1200/PO.20.00417
- language
- English
- LU publication?
- no
- id
- d416dff8-f85a-4184-b7a0-eccbca4a5171
- date added to LUP
- 2021-04-08 10:04:45
- date last changed
- 2024-09-07 17:32:58
@article{d416dff8-f85a-4184-b7a0-eccbca4a5171, author = {{Pfaff, Elke and de Beaumais, Tiphaine Adam and Marchais, Antonin and van Tilburg, Cornelis M. and Blattner-Johnson, Mirjam and Dirksen, Uta and Ora, Ingrid and Geoerger, Birgit and Schleiermacher, Gudrun and Pfister, Stefan M. and Witt, Olaf and Jones, David T.W. and Vassal, Gilles}}, issn = {{2473-4284}}, language = {{eng}}, pages = {{450--454}}, publisher = {{American Society of Clinical Oncology}}, series = {{JCO Precision Oncology}}, title = {{NTRK Alterations in pediatric high-risk malignancies identified through European clinical sequencing programs constitute promising drug targets}}, url = {{http://dx.doi.org/10.1200/PO.20.00417}}, doi = {{10.1200/PO.20.00417}}, volume = {{5}}, year = {{2021}}, }